PE / VC
1991
$4 800 M
Seattle, Washington, United States
Investment Ticket
Investment Horizon
Investment Stage
Exit Strategy
Profile
GROWTH BUYOUTIntegrity, transparency and partnership are core to our long-term success.
The Frazier Growth Buyout team employs a thesis-driven, Executive in Residence-centric investment model which capitalizes on long-term secular trends
STRATEGY
IDEA GENERATION
Alongside industry thought leaders and executives, the Growth Buyout team generates investment theses through its annual Montana CEO Summit, bi-annual retreats and proactive outreach to the broader healthcare ecosystem.
INVESTMENT PROFILE
The firm invests in profitable, lower middle-market healthcare companies with $5-50 million in EBITDA and makes equity commitments ranging from $30-350 million. Investments take the form of buyouts, recapitalizations and corporate carveouts.
EXECUTIVE IN RESIDENCE
Leveraging its extensive network and human capital team, Frazier pairs proven executives with curated investment theses. This enables the pursuit of unique investment opportunities with the EIR assuming an Executive Chairman or CEO role.
CENTER OF EXCELLENCE TEAM
Serving as a shared resource to the fund's portfolio companies, the Frazier Center of Excellence team provides functional domain expertise in finance, human capital, legal, information technology and operations management.
OUR MISSION
To be the trusted capital partner to management teams and stakeholders who share our passion for creating and growing innovative companies that improve the quality, accessibility and affordability of healthcare.
OUR VISION
To be the world’s leading healthcare investment firm, improving the well-being of patients and all others we serve.
GROWTH BUYOUT STRATEGY
To partner actively with the most accomplished and innovative executive teams in the healthcare industry to develop compelling, growth-oriented companies which capitalize on long-term secular trends.
OUR CORE VALUES
Integrity
We choose the harder right over the easier wrong in serving the interests of patients, investors, portfolio companies, and other stakeholders in the healthcare ecosystem.
Empowerment
We invest in each other (early, often, and thoughtfully) and take ownership in a collaborative, compassionate and respectful manner to achieve firm goals.
Perseverance
We advance patient care with determination and purpose to positively impact our community.
Transparency
We promote constructively-candid and respectful dialogue to get to the right answers.
Social Impact
We will effect positive change in the areas of diversity, equity, inclusion, accessibility and the environment.
Performance
We deliver superior results to our investors and improved outcomes for everyone we serve.
Industry
Region of investment
Frazier Healthcare Partners Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Frazier Healthcare Growth Buyout Fund XI, L.P.
|
Private Equity (PE)
|
Healthcare Services
Medical Devices
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$5-10 m
|
$2300 M
|
November 2024
|
|
Frazier Life Sciences XI, L.P.
|
Venture Capital (VC)
|
Biotechnology
Medical Devices
Pharmaceuticals
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$987 M
|
March 2022
|
|
Healthcare Growth Buyout Fund X LP
|
Private Equity (PE)
|
Healthcare Services
Medical Devices
Pharmaceuticals
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$5-10 m
|
$1400 M
|
May 2021
|
|
Frazier Life Sciences X
|
Venture Capital (VC)
|
Healthcare Services
Medical Devices
Life Sciences
HealthTech
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$617 M
|
January 2020
|
|
Frazier Life Sciences IX
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
HealthTech
|
Pre-seed
Seed
|
North America
Europe
|
$5-10 m
|
$419 M
|
January 2018
|